BARD1 Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB100-319
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot, Immunoprecipitation
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
The immunogen recognized by this antibody maps to a region between residues 250 and 300 of human BRCA1-associated RING Domain 1 using the numbering given in entry NP_000456.1 (GeneID 580).
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for BARD1 Antibody - BSA Free
Western Blot: BARD1 Antibody [NB100-319]
Western Blot: BARD1 Antibody [NB100-319] - Detection of human BARD1 by western blot. Samples: Whole cell lysate (10 ug) from Jurkat, Hep-G2, K-562, MCF-7, and A-549 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-BARD1 antibody NB100-319 used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.Immunoprecipitation: BARD1 Antibody [NB100-319]
Immunoprecipitation: BARD1 Antibody [NB100-319] - Detection of human BARD1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from MCF-7 cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-BARD1 antibody NB100-319 (NB100-319 lot 4) used for IP at 6 ug per reaction. BARD1 was also immunoprecipitated by a previous lot of this antibody (NB100-319 lot 3). For blotting immunoprecipitated BARD1, NB100-319 was used at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.Western Blot: BARD1 Antibody - BSA Free [NB100-319] -
MitoT increases the expression of anti-apoptotic Bcl-2/BARD1 pathways. A Fold change of differentially expressed (DE) genes contained within the GO terms related to apoptosis, cell death, and/or responses to different stimuli. B qRT-PCR analysis of BARD1 mRNA expression levels in FACS-sorted CD3+ T cells after 24-h post-mitoception with MSC derived-MT (n = 4). C Representative western blots of BARD1 in FACS-sorted CD3+ MitoTpos cells and MitoTneg cells after 24 or 48 h post-mitoception. D Fold change quantification of proteins showed in C (n = 3). E Ingenuity Pathway analysis for Bcl-2 gene network for the DE genes denoted in A. F qRT-PCR of Bcl-2 family gene expression in FACS-sorted CD3+ MitoTpos cells and MitoTneg cells after 24 h post-mitoception (n = 4). For figures B and D: graphs show mean +/- SEM and statistical analysis by unpaired t-test. For figure F: graph shows mean +/- SEM and statistical analysis by unpaired Mann–Whitney test (*p < 0.05, relative to MitoTneg control). All replicates are biological Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39334383), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Applications for BARD1 Antibody - BSA Free
Application
Recommended Usage
Immunoprecipitation
2 - 10 ug/mg lysate
Western Blot
1:500 - 1:2500
Application Notes
*The investigator should determine the optimal working dilution for a specific application.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris-Citrate/Phosphate (pH 7.0 - 8.0)
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: BARD1
Long Name
BRCA1 associated RING domain 1
Alternate Names
BARD-1, BRCA1 associated RING domain 1, BRCA1-associated RING domain gene 1, BRCA1-associated RING domain protein 1, EC 6.3.2.-
Entrez Gene IDs
580 (Human)
Gene Symbol
BARD1
UniProt
Additional BARD1 Products
Product Documents for BARD1 Antibody - BSA Free
Product Specific Notices for BARD1 Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...